Sage Therapeutics Inc. News
Biogen Beats on Third Quarter Earnings and Raises Guidance
Biogen posts third-quarter earnings that beat forecasts and also ups its full-year profit forecast amid strong expected demand for its Alzheimer's treatment drug.
Premarket Movers Tuesday: Sage Therapeutics, MicroStrategy
Stocks moving in premarket trading Tuesday include Sage Therapeutics, Freeport-McMoRan, MicroStrategy, ContextLogic and Fastenal.
Sage Therapeutics Plunges After Depression Drug-Trial Results
Sage Therapeutics shares plunge following disappointing test results for its depression drug Zuranolone that it is producing with drug giant Biogen.
Sage Falls as Some Patients Drop Out of Tremor Treatment Study
Nearly 40% of patients left a Sage Therapeutics study of a treatment for tremors due to side effects.
Sage Therapeutics Rises After Swing to Profit on Biogen Deal
Sage Therapeutics traded higher after the biopharma posted a fourth-quarter profit, benefiting from its collaboration with Biogen.
10 Worst Stocks in the Nasdaq on Thursday: Moderna Drops
The worst-performing stocks in the Nasdaq on Thursday included Moderna, eBay, and Zoom Video, among others.
7 Best Stocks in the Nasdaq on Wednesday: Splunk Rises
The best-performing stocks in the Nasdaq on Wednesday included Splunk, Expedia, and Fox Corporation, among others.
Sage Therapeutics Draws Negative Commentary on Biogen Deal
Sage shares fell as two analysts offered negative assessments of its agreement with Biogen to work together on Sage's depression drug.
Sage to Get $1.53 Billion From Biogen for Depression Drug Development
The companies will develop Sage’s zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders.
Domino's Pizza, Expedia: Latest Upgrades and Downgrades
TheStreet's weekly guide to upgrades, downgrades and price-target changes includes Domino's Pizza, Expedia, and Dave & Buster's.
Breaking News
Uber Makes a Change That Will Upset Riders
Frequent riders of Uber are about to lose something they really like.
Is This Synthetic Biology Pioneer On The Right Track?
Amyris is showing progress in one key area, but it may not be enough.
'Pharma Bro' Martin Shkreli's Crypto Conversion Turns Sour
The disgraced investor and convicted felon launched a cryptocurrency last July after his release from prison.
Over 1.7 Million Fords And Lincolns Are At Risk Of Being Recalled
The National Highway Transit Safety Administration received over 50 complaints over brake hose ruptures.